Prof Noreen Starling

So it's very dominant and the inhibition is powerful in pancreas cancer.

Colorectal cancer could be a bit more challenging because the circuitry is somewhat difficult.

What we sometimes see with these targeted drugs is it's a bit like whack-a-mole.

You press one thing down and another thing pops up in terms of resistance.

And that's, again, a challenge to the scientists in the field for how we manage that.

So again, very evolving field.

It's really exciting.

And I wanted to see this in my career time.

You know, when I started as a consultant 12 years ago, and I thought about what the challenges were and what I would love to see in terms of transformation, much like we saw in terms of melanoma and immunotherapy transformation.

And I think this is it.

Melanoma was a devastating condition when patients presented with stage four disease.

You know, when I was in training, patients would survive less than a year.

And now we're curing well over half of the patients with immunotherapy.

It does mark a real shift in time.

It's historic that the undruggable became druggable.

So if RAS can be unlocked and druggable, I think that shifts our thinking.

Is no target undruggable?

Can we target every possible molecule that is important and a driver for cancers and across all cancers?

So honestly, I think it's one of the most exciting times to be in clinical trials and cancer research.

And I think it gives me a lot of hope and I'm hoping it gives our patients and their families a lot of hope.